ASOs are broadly explored as potential drugs in therapeutic interventions for DM1 as they directly target the cause of the disease at the RNA level, namely toxic DMPK transcripts bearing extended repeats. The gene discussed is DMPK; the disease is myotonic dystrophy type 1.